Platelet activation and inflammatory response in patients with non-dipper hypertension

Atherosclerosis

Volumn 209, Issue 1, 2010, Pages 278-282

  Kaya, Mehmet Gungor ^a   Yarlioglues, Mikail ^a   Gunebakmaz, Ozgur ^a   Gunturk, Ertugrul ^a   Inanc, Tugrul ^a   Dogan, Ali ^a   Kalay, Nihat ^a   Topsakal, Ramazan ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Mean platelet volume; Non dipper hypertension; Platelet activation

Indexed keywords

C REACTIVE PROTEIN; EDETIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CIRCADIAN RHYTHM; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOCYTE ACTIVATION;

ATHEROSCLEROSIS; BLOOD PLATELETS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CELL SIZE; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; PLATELET ACTIVATION;

EID: 77049104887     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.09.010     Document Type: Article

References (38)

1. Hermida R.C. Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol Int 24 4 (2007) 749-775
2. Verdecchia P., Schillaci G., Guerrieri M., et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81 (1990) 528-536
3. Shimada K., Kawamoto A., Matsubayahi K., Mishinaga M., Kimura S., and Ozawa T. Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 10 8 (1992) 875-878
4. Fukuda M., Munemura M., Usami T., et al. Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 65 2 (2004) 621-625
5. Baumgart P., Walger P., Gemen S., von Eiff M., Raidt H., and Rahn K.H. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 57 (1991) 293-298
6. Takakuwa H., Ise T., Kato T., et al. Diurnal variation of hemodynamic indices in non-dipper hypertensive patients. Hypertens Res 24 3 (2001) 195-201
7. Seo H.S., Kang T.S., Park S., et al. Non-dippers are associated with adverse cardiac remodeling and dysfunction. In J Cardiol 112 (2006) 171-177
8. Tsiara S., Elisaf M., Jagroop I.A., and Mikhailidis D.P. Platelets as predictor of vascular risk: is there a practical index of platelet activity?. Clin Appl Thromb Hemost 9 (2003) 177-190
9. Thombson C.B., Eaton K., Princiotta S.M., Rushin C.A., and Valeri C.R. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 50 (1982) 509-519
10. Cameron H.A., Phillips R., Ibbotson R.M., and Carson P.H. Platelet size in myocardial infarction. Br Med J 287 6390 (1983) 449-451
11. Pizzulli L., Yang A., Martin J.F., and Lüderitz B. Changes in platelet size and count in unstable angina pectoris compared to stable or non-cardiac chest pain. Eur Heart J 19 (1998) 80-84
12. Celik T., Yuksel U.C., Iyisoy A., et al. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol 116 2 (2007) 206-211
13. Bath P., Algert C., Chapman N., and Neal B. PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of CVD. Stroke 35 (2004) 622-626
14. Park Y., Schoene N., and Haris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 13 (2002) 301-306
15. Martin J.F., Bath P.M., and Burr M.L. Influence of platelet size on outcome after myocardial infarction. Lancet 338 (1991) 1409-1411
16. Pabón Osuna P., Nieto Ballesteros F., Moríñigo Muñoz J.L., et al. The effect of mean platelet volume on the short term prognosis of acute myocardial infarction. Res Esp Cardiol 51 (1998) 816-822
17. Pearson T.A., Mensah G.A., Alexander R.W., et al. Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and American Heart Association. Circulation 107 (2003) 499-511
18. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and preventation. Circulation 107 (2003) 363-369
19. Joint National Committee. The seventh report of the Joint National Committee on detection, evaluation and treatment of high blood pressure (JNC 7). J Am Med Assoc 289 (2003) 2560-2572
20. Kannel W.B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 275 (1996) 1571-1576
21. Verdecchia P., Schillaci G., Reboldi G., Franklin S.S., and Porcellati C. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 103 21 (2001) 2579-2584
22. Verdecchia P., Reboldi G., Porcellati C., et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subject. J Am Coll Cardiol 39 (2002) 878-885
23. Martin J.F., Trowbridge E.A., Salmon G., and Plumb J. The biological significance of platelet volume; its relationship to bleeding time, TXA2 production and megakaryocyte nuclear DNA concentration. Thromb Res 32 (1983) 443-460
24. Erhart S., Beer J.H., and Reinhart W.H. Influence of aspirin on platelet count and volume in human. Acta Haematol 101 (1999) 140-144
25. Nadar S.K., Blann A.D., Kamath S., Beevers D.G., and Lip G.Y. Platelet indexes in relation to target organ damage in high risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 44 (2004) 415-422
26. Giles C., and Inglis T.C. Thrombocytopenia and macrothrombocytosis in gestational hypertension. Br J Obstet Gynaecol 88 (1981) 1115-1119
27. Coban E., Yazi{dotless}ci{dotless}oglu G., Avci{dotless} A.B., and Akci{dotless}t F. The mean platelet volume in patients with essential and white coat hypertension. Platelets 16 7 (2005) 435-438
28. Tavil Y., Sen N., Yazici H.U., Hizal F., Abaci A., and Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. Thromb Res 120 (2007) 245-250
29. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135
30. Buffon A., Biasucci L.M., Liuzzo G., D'Onofrio G., Crea F., and Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 347 1 (2002) 5-12
31. Clearfield M.B. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 105 9 (2005) 409-416
32. Tsioufis C., Syrseloudis D., Dimitriadis K., et al. Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J Hum Hypertens 22 7 (2008) 501-508
33. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
34. Von Hundelshausen P., Weber K.S., et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103 (2001) 1772-1777
35. Brody J.I., Pickering N.J., Capuzzi D.M., Fink G.B., Can C.A., and Gomez F. Interleukin-1 as a factor in occlusive vascular disease. Am J Clin Pathol 97 (1992) 8-13
36. Simon D.I., Chen Z., Xu H., et al. Platelet glycoprotein Ib is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 192 (2000) 193-204
37. Dastjerdi M.S., Emami T., Najafian A., and Amini M. Mean platelet volume measurement, EDTA or citrate?. Hematology 11 (2006) 317-319
38. Macey M., Azam U., McCarthy D., et al. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem 48 (2002) 891-899